<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Treatments for Diabetic Foot Ulcers</segment>
<segment id="2" parent="1002" relname="same_unit">One strategy for the management of patients with a DFU</segment>
<segment id="3" parent="1003" relname="joint">is to introduce a multidisciplinary approach</segment>
<segment id="4" parent="1004" relname="span">and address the multifactorial processes</segment>
<segment id="5" parent="4" relname="elaboration">involved in DFUs .</segment>
<segment id="6" parent="1008" relname="span">The use of multi-disciplinary teams</segment>
<segment id="7" parent="6" relname="restatement">( MDTs )</segment>
<segment id="8" parent="1009" relname="span">that include all relevant specialties</segment>
<segment id="9" parent="8" relname="elaboration">( i. e. , nursing , orthopedics , plastic surgery , vascular surgery , nutrition , and endocrinology departments )</segment>
<segment id="10" parent="1011" relname="span">has shown an effect</segment>
<segment id="11" parent="10" relname="elaboration">of decreasing the risks</segment>
<segment id="12" parent="1012" relname="joint">associated with DFUs and amputation by 50 – 85 % ,</segment>
<segment id="13" parent="1013" relname="joint">lowering costs ,</segment>
<segment id="14" parent="1013" relname="joint">and leading to a better quality of life for patients with DFUs .</segment>
<segment id="15" parent="1014" relname="joint">Management of DFUs requires the correct classification of stage and severity .</segment>
<segment id="16" parent="1016" relname="joint">Adequate care for DFUs should include a focus on DM control as well as on wound care , proper infection control , relieving pressure ,</segment>
<segment id="17" parent="1016" relname="joint">and optimizing blood flow .</segment>
<segment id="18" parent="1017" relname="span">The basic care for the control and treatment of DFUs is focused on the management of adequate perfusion , pressure mitigation , control of infection , and debridement .</segment>
<segment id="19" parent="1019" relname="span">With technological advancement , other series of therapies for DFUs have been implemented , such as the development of skin substitutes , negative pressure wound therapy , hyperbaric oxygen , the creation of new wound dressings</segment>
<segment id="20" parent="19" relname="elaboration">that include growth factors , and the use of tissues from bioengineering .</segment>
<segment id="21" parent="1020" relname="joint">In this way , treatments for DPN , PAD , and infections have provided encouraging results .</segment>
<segment id="22" parent="1021" relname="joint">4.1 .</segment>
<segment id="23" parent="1023" relname="preparation">Treatments for Diabetic Peripheral</segment>
<segment id="24" parent="1024" relname="preparation">Neuropathy</segment>
<segment id="25" parent="1026" relname="span">DPN is a factor</segment>
<segment id="26" parent="25" relname="elaboration">that increases the risk of the appearance of a DFU ,</segment>
<segment id="27" parent="28" relname="attribution">owing to the loss of sensation in the limb ,</segment>
<segment id="28" parent="1027" relname="span">making patients vulnerable to trauma .</segment>
<segment id="29" parent="1028" relname="joint">Tight glycemic control is the primary step and a main feature of DPN management .</segment>
<segment id="30" parent="1030" relname="preparation">Normoglycemia is more effectively restored by a pancreas transplant .</segment>
<segment id="31" parent="1031" relname="span">Several studies have demonstrated improvement of motor and sensory neuropathy in patients with DPN</segment>
<segment id="32" parent="31" relname="circumstance">after they were treated with a pancreas transplant .</segment>
<segment id="33" parent="1032" relname="joint">However , discrepancies exist in the time of response .</segment>
<segment id="34" parent="1035" relname="span">Pharmacological treatment is used for painful DPN</segment>
<segment id="35" parent="34" relname="elaboration">manifested as numbness , burning , stabbing , or excruciating or intractable pain ;</segment>
<segment id="36" parent="1037" relname="span">only three treatments are approved by the U.S. Food and Drug Administration for the pain</segment>
<segment id="37" parent="36" relname="elaboration">associated with DPN ,</segment>
<segment id="38" parent="1037" relname="elaboration">namely , pregabalin , tapentadol , and duloxetine .</segment>
<segment id="39" parent="1039" relname="span">Another pharmacological therapy includes analgesics , such as tramadol , acetaminophen , and some opioids such as oxycodone ,</segment>
<segment id="40" parent="1040" relname="joint">which have constipation and nausea as side effects ,</segment>
<segment id="41" parent="1041" relname="span">and must be taken with care</segment>
<segment id="42" parent="41" relname="cause">because they can be misused .</segment>
<segment id="43" parent="1042" relname="joint">Therapy with antidepressants such as amitriptyline , nortriptyline , and venlafaxine , among others ,</segment>
<segment id="44" parent="1044" relname="joint">has shown an efficacy in neuropathic pain management .</segment>
<segment id="45" parent="1044" relname="joint">It has an effect on the recapture of noradrenaline and serotonin , as well as on muscarinic effects .</segment>
<segment id="46" parent="1047" relname="circumstance">In spite of this ,</segment>
<segment id="47" parent="1047" relname="span">there are limited studies</segment>
<segment id="48" parent="1048" relname="span">evaluating these drugs</segment>
<segment id="49" parent="48" relname="cause">because their doses in clinical trials are not entirely reproducible in clinical practice .</segment>
<segment id="50" parent="1052" relname="span">Alpha-lipoic acid</segment>
<segment id="51" parent="50" relname="restatement">( ALA )</segment>
<segment id="52" parent="1051" relname="same_unit">has been suggested as a potential therapeutic agent</segment>
<segment id="53" parent="1053" relname="joint">in treating DPN ;</segment>
<segment id="54" parent="1053" relname="joint">its antioxidant capacity seems to delay or reverse damages to peripheral nerves .</segment>
<segment id="55" parent="1056" relname="span">Several human randomized controlled trials</segment>
<segment id="56" parent="55" relname="elaboration">( RCTs )</segment>
<segment id="57" parent="1055" relname="same_unit">have investigated the effects of ALA in the development of diabetic nephropathy .</segment>
<segment id="58" parent="1060" relname="span">A meta-analysis of four RCTs</segment>
<segment id="59" parent="58" relname="elaboration">( n = 653 )</segment>
<segment id="60" parent="1059" relname="same_unit">showed</segment>
<segment id="61" parent="1061" relname="span">that ,</segment>
<segment id="62" parent="1063" relname="span">compared with placebo , intravenous ALA</segment>
<segment id="63" parent="62" relname="elaboration">( 600 mg per day )</segment>
<segment id="64" parent="1064" relname="span">decreased symptoms of neuropathy</segment>
<segment id="65" parent="1065" relname="contrast">when administered for three weeks ,</segment>
<segment id="66" parent="1067" relname="span">but symptom improvement with oral ALA</segment>
<segment id="67" parent="66" relname="elaboration">( &gt;600 mg per day for 3 – 5 weeks )</segment>
<segment id="68" parent="1066" relname="same_unit">was not clinically significant .</segment>
<segment id="69" parent="1069" relname="span">There is no evidence</segment>
<segment id="70" parent="69" relname="elaboration">evaluating long-term treatment .</segment>
<segment id="71" parent="1071" relname="span">Currently , treatments</segment>
<segment id="72" parent="1073" relname="span">based on the use of mesenchymal stem cells</segment>
<segment id="73" parent="72" relname="restatement">( MSC )</segment>
<segment id="74" parent="1074" relname="same_unit">derived from adipose tissue</segment>
<segment id="75" parent="1074" relname="same_unit">have been considered as a potential treatment against DPN .</segment>
<segment id="76" parent="1076" relname="span">These therapies promote the production of pro-angiogenic , neuroprotective , and anti-inflammatory factors ,</segment>
<segment id="77" parent="76" relname="elaboration">which have a positive impact on the clinical manifestations of the disease .</segment>
<segment id="78" parent="1078" relname="span">On the other hand , the use of biological therapy with low doses of IL-6 has been demonstrated</segment>
<segment id="79" parent="1079" relname="joint">to promote improvement of blood flow , decrease chronic inflammation ,</segment>
<segment id="80" parent="1079" relname="joint">and regenerate peripheral nerve fibers .</segment>
<segment id="81" parent="1081" relname="preparation">Accordingly , IL-6 may prove to be an effective treatment for the protection and/or restoration of peripheral nerve function in DPN ;</segment>
<segment id="82" parent="1082" relname="preparation">see Table 1 .</segment>
<segment id="83" parent="1082" relname="joint">4.2 .</segment>
<segment id="84" parent="1084" relname="span">Treatments for Peripheral Arterial Disease</segment>
<segment id="85" parent="84" relname="elaboration">( Ischemia )</segment>
<segment id="86" parent="1086" relname="preparation">Ischemia presenting in diabetic patients</segment>
<segment id="87" parent="1086" relname="span">due to a reduction in blood flow</segment>
<segment id="88" parent="1088" relname="span">that occurs in both small vessels</segment>
<segment id="89" parent="88" relname="elaboration">( microvascular , such as capillaries )</segment>
<segment id="90" parent="1090" relname="span">and large vessels</segment>
<segment id="91" parent="90" relname="elaboration">( macrovascular , such as arteries and veins ) ,</segment>
<segment id="92" parent="1091" relname="same_unit">or due to a decrease of angiogenesis ,</segment>
<segment id="93" parent="1093" relname="span">can be treated through revascularization of at least one of the foot arteries</segment>
<segment id="94" parent="1094" relname="span">to try to restore blood flow in patients with a DFU</segment>
<segment id="95" parent="1095" relname="span">whose toe pressure is &lt;30 mmHg or transcutaneous oxygen pressure</segment>
<segment id="96" parent="95" relname="restatement">( TcPO2 )</segment>
<segment id="97" parent="1096" relname="joint">&lt;25 mmHg ,</segment>
<segment id="98" parent="1098" relname="span">as well as in those</segment>
<segment id="99" parent="98" relname="elaboration">who have a DFU</segment>
<segment id="100" parent="1099" relname="span">that does not heal with pressure on the ankle of &lt;50 mmHg or ankle-brachial index</segment>
<segment id="101" parent="100" relname="elaboration">( ABI ) &lt;0.5 .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="multinuc" parent="1002" relname="same_unit"/>
<group id="1004" type="span" parent="1003" relname="joint"/>
<group id="1005" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1006" type="multinuc" parent="1005" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1008" relname="elaboration"/>
<group id="1010" type="multinuc" parent="1006" relname="same_unit"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="multinuc" parent="1010" relname="same_unit"/>
<group id="1013" type="multinuc" parent="1012" relname="joint"/>
<group id="1014" type="multinuc" parent="1005" relname="joint"/>
<group id="1015" type="multinuc" parent="1014" relname="joint"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="span" parent="1015" relname="joint"/>
<group id="1018" type="multinuc" parent="18" relname="elaboration"/>
<group id="1019" type="span" parent="1018" relname="sequence"/>
<group id="1020" type="multinuc" parent="1018" relname="sequence"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1024" type="multinuc" parent="1023" relname="span"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="span"/>
<group id="1027" type="span" parent="1026" relname="elaboration"/>
<group id="1028" type="multinuc" parent="1024" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1030" relname="joint"/>
<group id="1033" type="multinuc" parent="1032" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="span" parent="1035" relname="elaboration"/>
<group id="1037" type="span" parent="1036" relname="span"/>
<group id="1038" type="multinuc" parent="1033" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="joint"/>
<group id="1040" type="multinuc" parent="39" relname="elaboration"/>
<group id="1041" type="span" parent="1040" relname="joint"/>
<group id="1042" type="multinuc" parent="1038" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="joint"/>
<group id="1044" type="multinuc" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1043" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="span" parent="47" relname="elaboration"/>
<group id="1049" type="multinuc" parent="1045" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="multinuc" parent="1050" relname="span"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="multinuc" parent="1051" relname="purpose"/>
<group id="1054" type="multinuc" parent="1049" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="multinuc" parent="1054" relname="joint"/>
<group id="1058" type="span" parent="1057" relname="joint"/>
<group id="1059" type="multinuc" parent="1061" relname="attribution"/>
<group id="1060" type="span" parent="1059" relname="same_unit"/>
<group id="1061" type="span" parent="1058" relname="span"/>
<group id="1062" type="multinuc" parent="61" relname="elaboration"/>
<group id="1063" type="span" parent="1062" relname="same_unit"/>
<group id="1064" type="span" parent="1062" relname="same_unit"/>
<group id="1065" type="multinuc" parent="64" relname="circumstance"/>
<group id="1066" type="multinuc" parent="1065" relname="contrast"/>
<group id="1067" type="span" parent="1066" relname="same_unit"/>
<group id="1068" type="multinuc" parent="1057" relname="joint"/>
<group id="1069" type="span" parent="1068" relname="joint"/>
<group id="1070" type="multinuc" parent="1068" relname="joint"/>
<group id="1071" type="span" parent="1070" relname="joint"/>
<group id="1072" type="multinuc" parent="71" relname="elaboration"/>
<group id="1073" type="span" parent="1072" relname="same_unit"/>
<group id="1074" type="multinuc" parent="1072" relname="same_unit"/>
<group id="1075" type="multinuc" parent="1070" relname="joint"/>
<group id="1076" type="span" parent="1075" relname="sequence"/>
<group id="1077" type="multinuc" parent="1075" relname="sequence"/>
<group id="1078" type="span" parent="1077" relname="joint"/>
<group id="1079" type="multinuc" parent="78" relname="purpose"/>
<group id="1080" type="span" parent="1077" relname="joint"/>
<group id="1081" type="span" parent="1080" relname="span"/>
<group id="1082" type="multinuc" parent="1081" relname="span"/>
<group id="1083" type="span" parent="1082" relname="joint"/>
<group id="1084" type="span" parent="1085" relname="preparation"/>
<group id="1085" type="span" parent="1083" relname="span"/>
<group id="1086" type="span" parent="1085" relname="span"/>
<group id="1087" type="multinuc" parent="87" relname="elaboration"/>
<group id="1088" type="span" parent="1087" relname="joint"/>
<group id="1089" type="multinuc" parent="1087" relname="joint"/>
<group id="1090" type="span" parent="1089" relname="same_unit"/>
<group id="1091" type="multinuc" parent="1089" relname="same_unit"/>
<group id="1092" type="multinuc" parent="1091" relname="same_unit"/>
<group id="1093" type="span" parent="1092" relname="same_unit"/>
<group id="1094" type="span" parent="93" relname="purpose"/>
<group id="1095" type="span" parent="94" relname="elaboration"/>
<group id="1096" type="multinuc" parent="1092" relname="same_unit"/>
<group id="1097" type="span" parent="1096" relname="joint"/>
<group id="1098" type="span" parent="1097" relname="span"/>
<group id="1099" type="span" parent="1098" relname="elaboration"/>
	</body>
</rst>
